Evidence map›Paper›PMID 42016588›Full record

ArticlePEC innovation2026

Pretest-posttest trial of a lung cancer screening decision aid for individuals with multimorbidity from a primary care population.

Kyle M Koster, Francesca Minardi, Abigail Feinberg, Mara Schonberg, Julie B Schnur, Juan P Wisnivesky, Michael A Diefenbach, Minal S Kale

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PEC innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kyle M KosterDivision of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
Francesca MinardiDivision of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
Abigail FeinbergDivision of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
Mara SchonbergDivision of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
Julie B SchnurDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
Juan P WisniveskyDivision of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
Michael A DiefenbachInstitute of Health System Science, Feinstein Institutes for Medical Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 330 Community Dr., Manhasset, NY 11030, USA.
Minal S KaleDivision of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.

Funding

Research and mentoring program in shared decision making in the care of older adultsK24AG071906 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SCHONBERG, MARA A · 2021 to 2025
$946k
NIA NIH HHS K24 AG071906
6 · The paper itself

Abstract

Objective: This study pilot tested a novel Decision Aid (DA) that clarifies the impact of multimorbidity on Lung Cancer Screening (LCS) risks and benefits. Outcomes of interest include LCS knowledge, disposition to complete LCS, decisional conflict and confidence. Methods: Evaluation scales were administered before and after DA exposure to 50 patients with smoking history; 70% of them having moderate or severe multimorbidity. Results: LCS Knowledge Measure scores improved (median 3 vs. 5 on scale 0-12, Conclusion: Exposure to a DA tailored to individuals with multimorbidity was associated with improved knowledge of LCS. Further investigation is needed to evaluate the DA efficacy in patients with higher baseline decisional conflict and lower baseline confidence. Innovation: A novel DA presenting information on the impact of comorbidities on LCS risks and benefits was found to hold potential for better supporting the decision-making of patients with multimorbidity.

Indexed as

Decision aidLung cancer screeningPrimary care

Identifiers

PMID42016588
PMCPMC13092692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.